A spectrum of obesity requires precision

Obesity is a hot topic, and a focal research area, in the twentieth century. With over 40% of adults in the US afflicted and obesity costing the US healthcare system up to $210 billion per year in medical expenses, GLP-1s seem to be a miracle option – but they come at a cost.

In this latest pharmaphorum podcast, web editor Nicole Raleigh speaks with Michael Kyle, chief medical officer at Currax Pharmaceuticals – a company working to advance a greater understanding of how to effectively treat obesity – about perceptions and options beyond the bounds of GLP-1s, including evolution of hypertension treatments.

It is, as Kyle states, important to fundamentally understand that there are different types of obesity. Only since 2012 has obesity been classified as a disease, but, in addition to genetics, there are environmental and psychological factors that have impact, also. It is not a one-size-fits-all scenario and precision medicine is necessary.

The need for specific medical training in obesity is critical as well and, although this is changing, it is as yet inadequate. Additionally, early intervention is key.

You can listen to episode 143a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your podcasts!